[1] VIRANI S S, ALONSO A, APARICIO H J, et al. Heart disease and stroke statistics-2021 update: a report from the American heart association[J]. Circulation,2021,143(8):e254-e743.
[2] PONIKOWSKI P, VOORS A A, ANKER S D, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail,2016,18(8):891-975. doi:  10.1002/ejhf.592
[3] GUPTA A, HOUSTON B. A comprehensive review of the bioenergetics of fatty acid and glucose metabolism in the healthy and failing heart in nondiabetic condition[J]. Heart Fail Rev,2017,22(6):825-842. doi:  10.1007/s10741-017-9623-6
[4] RITTERHOFF J, TIAN R. Metabolism in cardiomyopathy: every substrate matters[J]. Cardiovasc Res,2017,113(4):411-421. doi:  10.1093/cvr/cvx017
[5] SANO H I, TOKI T, NAITO Y, et al. Developmental changes in the balance of glycolytic ATP production and oxidative phosphorylation in ventricular cells: a simulation study[J]. J Theor Biol,2017,419:269-277. doi:  10.1016/j.jtbi.2017.02.019
[6] LOPASCHUK G D, JASWAL J S. Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation[J]. J Cardiovasc Pharmacol,2010,56(2):130-140. doi:  10.1097/FJC.0b013e3181e74a14
[7] DE CARVALHO A E T S, BASSANEZE V, FORNI M F, et al. Early postnatal cardiomyocyte proliferation requires high oxidative energy metabolism[J]. Sci Rep,2017,7(1):15434. doi:  10.1038/s41598-017-15656-3
[8] HEGGERMONT W A, PAPAGEORGIOU A P, HEYMANS S, et al. Metabolic support for the heart: complementary therapy for heart failure? Eur J Heart Fail,2016,18(12):1420-1429. doi:  10.1002/ejhf.678
[9] WISNESKI J A, STANLEY W C, NEESE R A, et al. Effects of acute hyperglycemia on myocardial glycolytic activity in humans[J]. J Clin Invest,1990,85(5):1648-1656. doi:  10.1172/JCI114616
[10] MURTHY M S, PANDE S V. Malonyl-CoA binding site and the overt carnitine palmitoyltransferase activity reside on the opposite sides of the outer mitochondrial membrane[J]. Proc Natl Acad Sci USA,1987,84(2):378-382. doi:  10.1073/pnas.84.2.378
[11] PETERZAN M A, LYGATE C A, NEUBAUER S, et al. Metabolic remodeling in hypertrophied and failing myocardium: a review[J]. Am J Physiol Heart Circ Physiol,2017,313(3):H597-H616. doi:  10.1152/ajpheart.00731.2016
[12] DOENST T, NGUYEN T D, ABEL E D. Cardiac metabolism in heart failure: implications beyond ATP production[J]. Circ Res,2013,113(6):709-724. doi:  10.1161/CIRCRESAHA.113.300376
[13] AERNI-FLESSNER L, ABI-JAOUDE M, KOENIG A, et al. GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle[J]. Cardiovasc Diabetol,2012,11:63. doi:  10.1186/1475-2840-11-63
[14] WANG Y, ZHU S, LIU H T, et al. Thyroxine alleviates energy failure, prevents myocardial cell apoptosis, and protects against doxorubicin-induced cardiac injury and cardiac dysfunction via the LKB1/AMPK/mTOR axis in mice[J]. Dis Markers,2019,2019:7420196.
[15] MIRÓ Ò, HERRERO-PUENTE P, PRIETO B, et al. The subset of patients with acute heart failure able to secrete relaxin-2 at pregnancy concentrations could have a longer survival: a pilot study[J]. Biomarkers,2018,23(6):573-579. doi:  10.1080/1354750X.2018.1463564
[16] ARAGÓN-HERRERA A, FEIJÓO-BANDÍN S, ABELLA V, et al. Serelaxin (recombinant human relaxin-2) treatment affects the endogenous synthesis of long chain poly-unsaturated fatty acids and induces substantial alterations of lipidome and metabolome profiles in rat cardiac tissue[J]. Pharmacol Res,2019,144:51-65. doi:  10.1016/j.phrs.2019.04.009
[17] LARSEN A H, JESSEN N, NØRRELUND H, et al. A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes[J]. Eur J Heart Fail,2020,22(9):1628-1637. doi:  10.1002/ejhf.1656
[18] JO W, KANG K K, CHAE S, et al. Metformin alleviates left ventricular diastolic dysfunction in a rat myocardial ischemia reperfusion injury model[J]. Int J Mol Sci,2020,21(4):1489. doi:  10.3390/ijms21041489
[19] SUN D, YANG F. Metformin improves cardiac function in mice with heart failure after myocardial infarction by regulating mitochondrial energy metabolism[J]. Biochem Biophys Res Commun,2017,486(2):329-335. doi:  10.1016/j.bbrc.2017.03.036
[20] BERTRAND L, GINION A, BEAULOYE C, et al. AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B[J]. Am J Physiol Heart Circ Physiol,2006,291(1):H239-H250. doi:  10.1152/ajpheart.01269.2005
[21] CUSTODIO J S Jr, DURAES A R, ABREU M, et al. SGLT2 inhibition and heart failure-current concepts[J]. Heart Fail Rev,2018,23(3):409-418. doi:  10.1007/s10741-018-9703-2
[22] KOSIBOROD M N, JHUND P S, DOCHERTY K F, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial[J]. Circulation,2020,141(2):90-99. doi:  10.1161/CIRCULATIONAHA.119.044138
[23] DE BOER R A, NÚÑEZ J, KOZLOVSKI P, et al. Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure[J]. Br J Clin Pharmacol,2020,86(7):1346-1356. doi:  10.1111/bcp.14248
[24] LEGCHENKO E, CHOUVARINE P, BORCHERT P, et al. PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation[J]. Sci Transl Med,2018,10(438):eaao0303. doi:  10.1126/scitranslmed.aao0303
[25] CHONG C R, CLARKE K, LEVELT E. Metabolic remodelling in diabetic cardiomyopathy[J]. Cardiovasc Res,2017,113(4):422-430. doi:  10.1093/cvr/cvx018
[26] HSIEH C C, LI C Y, HSU C H, et al. Mitochondrial protection by simvastatin against angiotensin II-mediated heart failure[J]. Br J Pharmacol,2019,176(19):3791-3804. doi:  10.1111/bph.14781
[27] CHO K I, KOO S H, CHA T J, et al. Simvastatin attenuates the oxidative stress, endothelial thrombogenicity and the inducibility of atrial fibrillation in a rat model of ischemic heart failure[J]. Int J Mol Sci,2014,15(8):14803-14818. doi:  10.3390/ijms150814803
[28] LI P, LUO S K, PAN C J, et al. Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate[J]. Mol Med Rep,2015,12(6):7899-7906. doi:  10.3892/mmr.2015.4466
[29] LABINSKYY V, BELLOMO M, CHANDLER M P, et al. Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure[J]. J Pharmacol Exp Ther,2007,321(1):165-171. doi:  10.1124/jpet.106.116871
[30] DHYANI N, SAIDULLAH B, FAHIM M, et al. Fenofibrate ameliorates neural, mechanical, chemical, and electrical alterations in the murine model of heart failure[J]. Hum Exp Toxicol,2019,38(10):1183-1194. doi:  10.1177/0960327119860173
[31] UNNO K, ISOBE S, IZAWA H, et al. Relation of functional and morphological changes in mitochondria to myocardial contractile and relaxation reserves in asymptomatic to mildly symptomatic patients with hypertrophic cardiomyopathy[J]. Eur Heart J,2009,30(15):1853-1862. doi:  10.1093/eurheartj/ehp184
[32] DALAL J J, MISHRA S. Modulation of myocardial energetics: an important category of agents in the multimodal treatment of coronary artery disease and heart failure[J]. Indian Heart J,2017,69(3):393-401. doi:  10.1016/j.ihj.2017.04.001
[33] NAGARA K, SUZUKI A, SHIGA T, et al. Long-term outcome of carvedilol therapy in Japanese patients with nonischemic heart failure[J]. Heart Vessels,2020,35(7):957-966. doi:  10.1007/s00380-020-01560-w
[34] PODBREGAR M, VOGA G. Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure[J]. J Card Fail,2002,8(6):369-378. doi:  10.1054/jcaf.2002.130238
[35] SPOLADORE R, FRAGASSO G, PERSEGHIN G, et al. Beneficial effects of beta-blockers on left ventricular function and cellular energy reserve in patients with heart failure[J]. Fundam Clin Pharmacol,2013,27(4):455-464. doi:  10.1111/j.1472-8206.2012.01029.x
[36] CARAFA V, ROTILI D, FORGIONE M, et al. Sirtuin functions and modulation: from chemistry to the clinic[J]. Clin Epigenetics,2016,8:61. doi:  10.1186/s13148-016-0224-3
[37] SANTOS C N, GOMES A, OUDOT C, et al. Pure polyphenols applications for cardiac health and disease[J]. Curr Pharm Des,2018,24(19):2137-2156. doi:  10.2174/1381612824666180608102344
[38] WANG J R, ZHOU H, YI X Q, et al. Total ginsenosides of Radix Ginseng modulates tricarboxylic acid cycle protein expression to enhance cardiac energy metabolism in ischemic rat heart tissues[J]. Molecules,2012,17(11):12746-12757. doi:  10.3390/molecules171112746
[39] BANSAL T, CHATTERJEE E, SINGH J, et al. Arjunolic acid, a peroxisome proliferator-activated receptor α agonist, regresses cardiac fibrosis by inhibiting non-canonical TGF-β signaling[J]. J Biol Chem,2017,292(40):16440-16462. doi:  10.1074/jbc.M117.788299
[40] TANG B, ZHANG J G, TAN H Y, et al. Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure[J]. Biosci Rep,2018,38(3):BSR20171036. doi:  10.1042/BSR20171036
[41] DONG Z W, ZHAO P, XU M, et al. Astragaloside IV alleviates heart failure via activating PPARα to switch glycolysis to fatty acid β-oxidation[J]. Sci Rep,2017,7:2691. doi:  10.1038/s41598-017-02360-5
[42] ZHANG R, XU Y, NIU H F, et al. Lycium barbarum polysaccharides restore adverse structural remodelling and cardiac contractile dysfunction induced by overexpression of microRNA-1[J]. J Cell Mol Med,2018,22(10):4830-4839. doi:  10.1111/jcmm.13740
[43] FAN S R, ZHANG J F, XIAO Q, et al. Cardioprotective effect of the polysaccharide from Ophiopogon japonicus on isoproterenol-induced myocardial ischemia in rats[J]. Int J Biol Macromol,2020,147((1):233-240.
[44] MA J N, MENG X L, KANG S Y, et al. Regulatory effects of the fruit extract of Lycium chinense and its active compound, betaine, on muscle differentiation and mitochondrial biogenesis in C2C12 cells[J]. Biomed Pharmacother,2019,118:109297. doi:  10.1016/j.biopha.2019.109297
[45] LUAN A, TANG F, YANG Y, et al. Astragalus polysaccharide attenuates isoproterenol-induced cardiac hypertrophy by regulating TNF-α/PGC-1α signaling mediated energy biosynthesis[J]. Environ Toxicol Pharmacol,2015,39(3):1081-1090. doi:  10.1016/j.etap.2015.03.014
[46] VAKHRUSHEVA O, SMOLKA C, GAJAWADA P, et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice[J]. Circ Res,2008,102(6):703-710. doi:  10.1161/CIRCRESAHA.107.164558
[47] ZHANG N N, LIAN Z Q, PENG X Y, et al. Applications of higenamine in pharmacology and medicine[J]. J Ethnopharmacol,2017,196:242-252. doi:  10.1016/j.jep.2016.12.033
[48] HUANG B W, YOU J G, QIAO Y, et al. Tetramethylpyrazine attenuates lipopolysaccharide-induced cardiomyocyte injury via improving mitochondrial function mediated by 14-3-3γ[J]. Eur J Pharmacol,2018,832:67-74. doi:  10.1016/j.ejphar.2018.05.019
[49] QI D K, YOUNG L H. AMPK: energy sensor and survival mechanism in the ischemic heart[J]. Trends Endocrinol Metab,2015,26(8):422-429. doi:  10.1016/j.tem.2015.05.010
[50] WEI H M, WU H J, YU W, et al. Shenfu Decoction as adjuvant therapy for improving quality of life and hepatic dysfunction in patients with symptomatic chronic heart failure[J]. J Ethnopharmacol,2015,169:347-355. doi:  10.1016/j.jep.2015.04.016
[51] RUSSELL R R 3rd, LI J, COVEN D L, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury[J]. J Clin Invest,2004,114(4):495-503. doi:  10.1172/JCI19297
[52] SUN J, ZHANG K, XIONG W J, et al. Clinical effects of a standardized Chinese herbal remedy, Qili Qiangxin, as an adjuvant treatment in heart failure: systematic review and meta-analysis[J]. BMC Complement Altern Med,2016,16:201. doi:  10.1186/s12906-016-1174-1